CryoCath Technologies
Arctic Front
With 400,000 new cases every year, Atrial Fibrillation is the most prevalent cardiac arrhythmia affecting over four million patients in the world. Farm developed the industrial design and human factors for the proximal portion of CryoCath’s minimally invasive Arctic Front balloon catheter, used to reduce or completely eliminate AF. The Arctic Front balloon catheter creates lesions in the antrum or at the ostium of the targeted pulmonary vein for the treatment of paroxysmal atrial fibrillation. Comfort, size, flexibility and ergonomics were imperative in the development of this product. Farm also developed the user feature to assist with balloon retraction.
Additional Information:
www.cryocath.com